Expense sheet
R&D expenses for FY2021 were Rs 16,541 million, or 8.7% of revenue, versus 8.8% in FY2020. SG&A accounted for 28.8% of sales in FY2021 versus 28.7% in FY2020
Increasing digital foot print
We continued to simplify and digitalize our core business processes across the organization and ended the year with nearly 80% digitalization of all core business processes. We expanded the digital footprint into regulatory and clinical processes resulting in faster cycle time and lower error rates. In manufacturing, we continued to expand implementation and adoption of the Manufacturing Execution System and the Laboratory Information Management Systems which result in paperless shop floor and labs, eliminates errors and improves productivity. We also digitalized safety processes and equipment lifecycle management across the plants.
Covid-19 related products
We have continued to play our role in the fight against COVID-19 by acting proactively to bring multiple preventive and curative treatment options, including a vaccine. Some of our major COVID-19 products are:Sputnik V vaccine: We partnered with the Russian Direct Investment Fund (RDIF), Russia?s sovereign wealth fund, for conducting clinical trials and distribution of Sputnik V vaccine in India. We successfully completed Phase III trial for the vaccine, which demonstrated efficacy at 91.6%, consistent safety and immunogenicity results. In April 2021 we received the Government of India?s approval for emergency use of Sputnik-V in India. We have launched Sputnik V in May 2021. Remdesivir: We signed a licensing agreement with Gilead Sciences, Inc. that grants Dr. Reddy?s the right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19, in 127 countries including India. We launched Remdesivir under the brand name ?Redyx?? in India in September 2020. With the surge of COVID-19 cases in the second wave, we ramped-up our capacities to increase the availability of the medicine. 2-deoxy-D-glucose : The 2-DG has been developed by Defence Research and Development Organization (DRDO), in collaboration with Dr. Reddy?s. The drug received emergency use as adjunct therapy for hospitalized moderate to severe COVID-19 patients.
Dr. Reddys - Dr. Reddy's Laboratories Share Price
- Open6,898.30
- High7,019.95
- Low6,889.10
- Prev Close6,999.30
- Volume3,56,832
- VWAP(₹)6,929.36
Dr. Reddys share price insights
Intraday fact check
In the last 19 years, only 0.74 % trading sessions saw intraday declines higher than 5 % .ROE Outperforming 5 Year Average
Company delivered ROE of 19.74% in year ending Mar 31, 2024 outperforming its 5 year avg. of 15.62%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 17.96% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)Sell Signal: Bears inching ahead
14 day moving crossover appeared yesterday. Average price decline of -2.18% within 7 days of this signal in last 5 years.Dr. Reddys Share Price Update
Dr. Reddy's Laboratories Ltd. share price moved down by -0.98% from its previous close of Rs 6,999.30. Dr. Reddy's Laboratories Ltd. stock last traded price is 6,931.15
Share Price Value Today/Current/Last 6,931.15 Previous Day 6,999.30
Dr. Reddys Share Price Returns
| 1 Day | -0.98% |
| 1 Month | 1.33% |
| 3 Months | 15.5% |
| 1 Year | 21.09% |
| 3 Years | 50.66% |
| 5 Years | 174.2% |
Key Metrics
| PE Ratio(x) | 20.78 |
| EPS - TTM(₹) | 333.59 |
| MCap(₹ Cr.) | 1,15,632 |
| MCap Rank | 5 |
| PB Ratio(x) | 4.13 |
| Div Yield(%) | 0.58 |
| Face Value(₹) | 5.00 |
| 52W High(₹) | 7,107.45 |
| 52W Low(₹) | 5,205.55 |
| MCap/Sales | 3.67 |
| Beta(1 Month) | 0.75 |
| BV/Share(₹) | 1,693.63 |
Dr. Reddys Share Recommendations
33 Analysts
SellSellHoldBuyStrong
Buy
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 |
| Buy | 4 | 4 | 5 | 6 |
| Hold | 9 | 9 | 8 | 9 |
| Sell | 10 | 10 | 9 | 8 |
| Strong Sell | 4 | 4 | 4 | 4 |
| # Analysts | 33 | 33 | 32 | 32 |
- Target₹8010
- OrganizationJM Financial
- BUY
Dr. Reddys News & Analysis
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
AnnouncementsIntimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requir..
AnnouncementsDisclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
AnnouncementsDisclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Announcements
Dr. Reddys Financials
Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 7,883.30 7,311.30 7,453.00 7,217.60 6,931.90 Total Income Growth (%) 7.82 -1.90 3.26 4.12 7.41 Total Expenses 5,946.80 5,650.30 5,587.20 5,269.80 5,049.10 Total Expenses Growth (%) 5.25 1.13 6.02 4.37 -0.94 EBIT 1,936.50 1,661.00 1,865.80 1,947.80 1,882.80 EBIT Growth (%) 16.59 -10.98 -4.21 3.45 38.76 Profit after Tax (PAT) 1,392.40 1,309.80 1,380.90 1,482.20 1,405.00 PAT Growth (%) 6.31 -5.15 -6.83 5.49 46.34 EBIT Margin (%) 24.56 22.72 25.03 26.99 27.16 Net Profit Margin (%) 17.66 17.91 18.53 20.54 20.27 Basic EPS (₹) 83.61 78.66 82.94 89.09 84.55 All figures in Rs Cr, unless mentioned otherwise
InsightsEmployee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 17.96% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 38,863.80 32,285.10 29,746.90 26,616.80 23,225.30 Total Assets Growth (%) 20.38 8.53 11.76 14.60 3.38 Total Liabilities 10,609.00 8,999.00 10,534.50 8,975.10 7,626.50 Total Liabilities Growth (%) 17.89 -14.58 17.37 17.68 -9.66 Total Equity 28,254.80 23,286.10 19,212.40 17,641.70 15,598.80 Total Equity Growth (%) 21.34 21.20 8.90 13.10 11.23 Current Ratio (x) 2.59 2.38 1.82 1.80 1.75 Total Debt to Equity (x) 0.06 0.05 0.16 0.15 0.11 Contingent Liabilities 2,091.80 997.40 936.80 1,077.40 1,040.60 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 4,543.30 5,887.50 2,810.80 3,570.30 2,984.10 Net Cash used in Investing Activities -4,028.30 -4,137.30 -2,638.70 -2,266.00 -492.30 Net Cash flow from Financing Activities -376.30 -2,686.10 -242.20 -29.80 -2,515.90 Net Cash Flow 132.80 -907.30 3.20 1,285.80 -26.60 Closing Cash & Cash Equivalent 710.70 577.90 1,485.20 1,482.00 196.20 Closing Cash & Cash Equivalent Growth (%) 22.98 -61.09 0.22 655.35 -11.94 Total Debt/ CFO (x) 0.36 0.19 1.10 0.75 0.60 All figures in Rs Cr, unless mentioned otherwise
InsightsDecrease in Cash from Investing
Company has used Rs 4028.3 cr for investing activities which is an YoY decrease of 2.63%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 19.74 19.35 11.35 11.06 12.98 Return on Capital Employed (%) 25.13 25.95 15.44 15.84 12.04 Return on Assets (%) 14.35 13.96 7.33 7.33 8.72 Interest Coverage Ratio (x) 51.59 51.85 44.39 42.90 19.61 Asset Turnover Ratio (x) 0.79 0.80 0.56 0.60 75.42 Price to Earnings (x) 18.42 17.09 32.89 38.61 25.58 Price to Book (x) 3.63 3.31 3.73 4.26 3.32 EV/EBITDA (x) 11.62 10.32 17.01 18.20 17.27 EBITDA Margin (%) 31.51 30.01 19.73 21.84 17.64 InsightsROE Outperforming 5 Year Average
Company delivered ROE of 19.74% in year ending Mar 31, 2024 outperforming its 5 year avg. of 15.62%. (Source: Consolidated Financials)
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Dr. Reddys Stock Performance -0.98 -1.86 0.76 16.19 20.00 50.66 175.91 Divis Labs Stock Performance -0.37 2.28 4.63 14.13 37.96 2.07 217.92 Cipla Stock Performance 0.03 1.50 2.77 9.40 31.71 75.19 248.64 Torrent Pharma Stock Performance 0.45 2.50 7.50 28.79 75.40 125.45 311.62 Cadila Healthcare Stock Performance -0.55 -6.10 -6.14 7.51 78.47 105.62 407.08 All values in %
Stock Returns vs Nifty 100
Stock gave a 3 year return of 50.66% as compared to Nifty 100 which gave a return of 54.68%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 50.66% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
MF Ownership as on 31 July 2024
810.06
Amount Invested (in Cr.)
1.32%
% of AUM
-9.43
% Change (MoM basis)
791.53
Amount Invested (in Cr.)
1.04%
% of AUM
0.00
% Change (MoM basis)
607.54
Amount Invested (in Cr.)
1.91%
% of AUM
80.00
% Change (MoM basis)
Dr. Reddys Futures & Options
Date Price Open Interest 26-09-2024Current
194.1519.15 (10.94%)
00 (0.00%)
163.05Open225.80High154.00Low175.00Close2,043Contracts Traded23,348.07Turnover (₹ Lakhs)Open Interest as of 05 Jul 2024
Date Price Open Interest 26-09-2024Current
7,045.0533.25 (0.47%)
3,875125 (3.23%)
6,988.60Open7,100.00High6,968.00Low7,011.80Prev Close7,273Contracts Traded63,710.11Turnover (₹ Lakhs)Open Interest as of 05 Jul 2024
Corporate Actions
Splits
Split: Old FV5.0| New FV:1.0
Jul 27, 2024
Board Meeting
Quarterly Results & Stock Split
Jul 23, 2024
Final
800%
May 07, 2024
Announced on Meeting on Jul 23, 2024 Jul 27, 2024 Quarterly Results & Stock Split Mar 22, 2024 May 07, 2024 Audited Results & Final Dividend Dec 21, 2023 Jan 30, 2024 Quarterly Results Sep 22, 2023 Oct 27, 2023 Quarterly Results Jun 21, 2023 Jul 26, 2023 Quarterly Results Announced on Ex-Date Dividend% May 07, 2024 Jul 16, 2024 800% May 10, 2023 Jul 11, 2023 800% May 19, 2022 Jul 11, 2022 600% May 14, 2021 Jul 09, 2021 500% May 20, 2020 Jul 13, 2020 500% Announced on Ex-Date May 31, 2006 Aug 28, 2006 Bonus Ratio: 1 share(s) for every 1 shares held Mar 24, 1994 Apr 08, 1994 Bonus Ratio: 2 share(s) for every 1 shares held Sep 30, 1992 Dec 04, 1992 Bonus Ratio: 1 share(s) for every 1 shares held Dec 03, 1991 - Bonus Ratio: 1 share(s) for every 2 shares held Announced on Ex-Date Jul 31, 2001 Oct 10, 2001 Split: Old FV10.0| New FV:5.0 Jul 27, 2024 - Split: Old FV5.0| New FV:1.0 No Data Available
Announced on Meeting on Jan 15, 2024 Feb 15, 2024 - Oct 16, 2023 Nov 16, 2023 - May 10, 2023 Jul 27, 2023 Book closure from Jul 12, 2023 to Jul 14, 2023 May 20, 2022 Jul 29, 2022 Book closure from Jul 13, 2022 to Jul 15, 2022 Feb 25, 2022 Mar 29, 2022 -
About
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 115,632.17 Crore) operating in Pharmaceuticals sector.
Dr. Reddy's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Spent Chemicals, Scrap, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.
For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 7,883.30 Crore, up 7.82 % from last quarter Total Income of Rs 7,311.30 Crore and up 13.72 % from last year same quarter Total Income of Rs 6,931.90 Crore. Company has reported net profit after tax of Rs 1,386.50 Crore in latest quarter.
The company’s top management includes Mr.G V Prasad, Mr.K Satish Reddy, Mr.Deepak Sapra, Mr.Erez Israeli, Mr.M V Ramana, Dr.Alpna Seth, Mr.Arun M Kumar, Dr.Claudio Albrecht, Dr.K P Krishnan, Ms.Kalpana Morparia, Mr.Leo Puri, Ms.Penny Wan, Mr.Sanjiv Mehta, Ms.Shikha Sharma, Mr.Parag Agarwal, Mr.M V Narasimham, Mr.K Randhir Singh. Company has S R Batliboi & Associates LLP as its auditors. As on 30-06-2024, the company has a total of 16.68 Crore shares outstanding.
About Dr. Reddys
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 115,632.17 Crore) operating in Pharmaceuticals sector. Dr. Reddy's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Spent Chemicals, Scrap, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 7,883.30 Crore, up 7.82 % from last quarter Total Income of Rs 7,311.30 Crore and up 13.72 % from last year same quarter Total Income of Rs 6,931.90 Crore. Company has reported net profit after tax of Rs 1,386.50 Crore in latest quarter.The company’s top management includes Mr.G V Prasad, Mr.K Satish Reddy, Mr.Deepak Sapra, Mr.Erez Israeli, Mr.M V Ramana, Dr.Alpna Seth, Mr.Arun M Kumar, Dr.Claudio Albrecht, Dr.K P Krishnan, Ms.Kalpana Morparia, Mr.Leo Puri, Ms.Penny Wan, Mr.Sanjiv Mehta, Ms.Shikha Sharma, Mr.Parag Agarwal, Mr.M V Narasimham, Mr.K Randhir Singh. Company has S R Batliboi & Associates LLP as its auditors. As on 30-06-2024, the company has a total of 16.68 Crore shares outstanding.
Industry
Key Indices Listed On
Nifty 50, Nifty 100, Nifty 200, Nifty 500, BSE 500
Address
8-2-337,Road No. 3,Hyderabad, Telangana - 500034
Executive Leadership
G V Prasad
Co-Chairman & Manag. DirectorK Satish Reddy
ChairmanDeepak Sapra
Chief Executive OfficerErez Israeli
Chief Executive OfficerAuditors
Brands
FAQs about Dr. Reddys share
- 1. What is Dr. Reddys share price and what are the returns for Dr. Reddys share?Dr. Reddys share price was Rs 6,931.15 as on 29 Aug, 2024, 03:59 PM IST. Dr. Reddys share price was down by 0.98% based on previous share price of Rs. 6962.95.
- 2. Who owns Dr. Reddys?
- Promoter holding have gone down from 26.66 (30 Sep 2023) to 26.65 (30 Jun 2024)
- Domestic Institutional Investors holding have gone down from 21.03 (30 Sep 2023) to 20.61 (30 Jun 2024)
- Foreign Institutional Investors holding have gone down from 28.19 (30 Sep 2023) to 27.68 (30 Jun 2024)
- Other investor holding has gone up from 24.12 (30 Sep 2023) to 25.06 (30 Jun 2024)
- 3. What dividend is Dr. Reddys giving?An equity Final dividend of Rs 40 per share was declared by Dr. Reddy's Laboratories Ltd. on 07 May 2024. So, company has declared a dividend of 800% on face value of Rs 5 per share. The ex dividend date was 16 Jul 2024.
- 4. What is 52 week high/low of Dr. Reddys share price?52 Week high of Dr. Reddys share is Rs 7,107.45 while 52 week low is Rs 5,205.55
- 5. Who is the chairman of Dr. Reddys?G V Prasad is the Co-Chairman & Manag. Director of Dr. Reddys
- 6. What are the Dr. Reddys quarterly results?On Consoldiated basis, Dr. Reddys reported a total income and profit of Rs 7883.30 Cr and Rs 1392.40 respectively for quarter ending 2024-06-30. Total Income and profit for the year ending 2024-03-31 was Rs 28905.40 Cr and Rs 5577.90 Cr.
- 7. What is the PE & PB ratio of Dr. Reddys?The PE ratio of Dr. Reddys stands at 20.98, while the PB ratio is 4.13.
- 8. Is Dr. Reddys a good buy?As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 33 analysts for Dr. Reddys stock is to Hold. Recommendation breakup is as follows
- 6 analysts are recommending Strong Buy
- 4 analysts are recommending to Buy
- 9 analysts are recommending to Hold
- 10 analysts are recommending to Sell
- 4 analysts are recommending Strong Sell
- 9. What are the key metrics to analyse Dr. Reddys Share Price?Key Metrics for Dr. Reddys are:
- PE Ratio of Dr. Reddys is 20.78
- Price/Sales ratio of Dr. Reddys is 3.67
- Price to Book ratio of Dr. Reddys is 4.13
- 10. Which are the key peers to Dr. Reddys?Top 10 Peers for Dr. Reddys are Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Divi's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Mankind Pharma Ltd., Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd. and Biocon Ltd.
- 11. Who is the CEO of Dr. Reddys?Deepak Sapra is the Chief Executive Officer of Dr. Reddys
- 12. What is the CAGR of Dr. Reddys?The CAGR of Dr. Reddys is 10.12.
- 13. What are the returns for Dr. Reddys share?Return Performance of Dr. Reddys Shares:
- 1 Week: Dr. Reddys share price moved down by 0.54%
- 3 Month: Dr. Reddys share price moved up by 15.50%
- 6 Month: Dr. Reddys share price moved up by 7.89%
- 14. What's the market capitalization of Dr. Reddys?Market Capitalization of Dr. Reddys stock is Rs 1,15,632 Cr.
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.